The researchers tested the RNA origami in a lipid vesicle, a simple cell model system widely used in biology. Using so-called RNA aptamers, the artificial cytoskeleton was bound to the cell membranes.

Japan's Ono Pharmaceutical bought an antisense oligonucleotide from Ionis Pharmaceuticals. Plus more. 1. 'I don't feel we lost momentum': Takeda’s oncology execs sharpen focus after ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer. The RNA-targeted ...

including RNA degradation. Created with BioRender.com. Current antisense therapies typically consist of short nucleic acid molecules less than 30 nucleotides in length and can be produced through ...

This manuscript provides a deep mutational scanning of the deaminase domain of human ADAR2 to provide a comprehensive assessment of amino acids that alter editing activity at a specific adenosine ...

The extent of non-coding RNA alterations in patients with sepsis and their relationship to clinical characteristics, soluble mediators of the host response to infection, as well as an advocated in ...